535 related articles for article (PubMed ID: 33683991)
1. Ivosidenib: an investigational drug for the treatment of biliary tract cancers.
Angelakas A; Lamarca A; Hubner RA; McNamara MG; Valle JW
Expert Opin Investig Drugs; 2021 Apr; 30(4):301-307. PubMed ID: 33683991
[No Abstract] [Full Text] [Related]
2. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Abou-Alfa GK; Macarulla T; Javle MM; Kelley RK; Lubner SJ; Adeva J; Cleary JM; Catenacci DV; Borad MJ; Bridgewater J; Harris WP; Murphy AG; Oh DY; Whisenant J; Lowery MA; Goyal L; Shroff RT; El-Khoueiry AB; Fan B; Wu B; Chamberlain CX; Jiang L; Gliser C; Pandya SS; Valle JW; Zhu AX
Lancet Oncol; 2020 Jun; 21(6):796-807. PubMed ID: 32416072
[TBL] [Abstract][Full Text] [Related]
3. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
Lowery MA; Burris HA; Janku F; Shroff RT; Cleary JM; Azad NS; Goyal L; Maher EA; Gore L; Hollebecque A; Beeram M; Trent JC; Jiang L; Fan B; Aguado-Fraile E; Choe S; Wu B; Gliser C; Agresta SV; Pandya SS; Zhu AX; Abou-Alfa GK
Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):711-720. PubMed ID: 31300360
[TBL] [Abstract][Full Text] [Related]
4. Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.
Corrigan L; Lowery M
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):475-481. PubMed ID: 33836133
[No Abstract] [Full Text] [Related]
5. Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study.
Fan B; Abou-Alfa GK; Zhu AX; Pandya SS; Jia H; Yin F; Gliser C; Hua Z; Hossain M; Yang H
Cancer Chemother Pharmacol; 2024 May; 93(5):471-479. PubMed ID: 38278871
[TBL] [Abstract][Full Text] [Related]
6. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
Zhu AX; Macarulla T; Javle MM; Kelley RK; Lubner SJ; Adeva J; Cleary JM; Catenacci DVT; Borad MJ; Bridgewater JA; Harris WP; Murphy AG; Oh DY; Whisenant JR; Lowery MA; Goyal L; Shroff RT; El-Khoueiry AB; Chamberlain CX; Aguado-Fraile E; Choe S; Wu B; Liu H; Gliser C; Pandya SS; Valle JW; Abou-Alfa GK
JAMA Oncol; 2021 Nov; 7(11):1669-1677. PubMed ID: 34554208
[TBL] [Abstract][Full Text] [Related]
7. Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-
Aguado-Fraile E; Tassinari A; Ishii Y; Sigel C; Lowery MA; Goyal L; Gliser C; Jiang L; Pandya SS; Wu B; Bardeesy N; Choe S; Deshpande V
Future Oncol; 2021 Jun; 17(16):2057-2074. PubMed ID: 33709779
[No Abstract] [Full Text] [Related]
8. Regorafenib, an investigational agent for the treatment of cholangiocarcinoma.
Sahin IH; Tan E; Kim R
Expert Opin Investig Drugs; 2021 Apr; 30(4):333-341. PubMed ID: 33378249
[TBL] [Abstract][Full Text] [Related]
9. Susan Pandya on investigational treatment approaches to cholangiocarcinoma.
Pandya Md S
Expert Opin Investig Drugs; 2021 Apr; 30(4):291-293. PubMed ID: 33302739
[No Abstract] [Full Text] [Related]
10. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
Fan B; Mellinghoff IK; Wen PY; Lowery MA; Goyal L; Tap WD; Pandya SS; Manyak E; Jiang L; Liu G; Nimkar T; Gliser C; Prahl Judge M; Agresta S; Yang H; Dai D
Invest New Drugs; 2020 Apr; 38(2):433-444. PubMed ID: 31028664
[TBL] [Abstract][Full Text] [Related]
11. Evaluating ivosidenib for the treatment of acute myeloid leukemia.
Donker ML; Ossenkoppele GJ
Expert Opin Pharmacother; 2020 Dec; 21(18):2205-2213. PubMed ID: 32808831
[TBL] [Abstract][Full Text] [Related]
12. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
Rizzo A; Ricci AD; Brandi G
Cancer Treat Res Commun; 2021; 27():100356. PubMed ID: 33799004
[TBL] [Abstract][Full Text] [Related]
13. Ivosidenib: First Global Approval.
Dhillon S
Drugs; 2018 Sep; 78(14):1509-1516. PubMed ID: 30209701
[TBL] [Abstract][Full Text] [Related]
14. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.
Lamarca A; Barriuso J; McNamara MG; Valle JW
J Hepatol; 2020 Jul; 73(1):170-185. PubMed ID: 32171892
[TBL] [Abstract][Full Text] [Related]
15. Clinical development of IDH1 inhibitors for cancer therapy.
Zarei M; Hue JJ; Hajihassani O; Graor HJ; Katayama ES; Loftus AW; Bajor D; Rothermel LD; Vaziri-Gohar A; Winter JM
Cancer Treat Rev; 2022 Feb; 103():102334. PubMed ID: 34974243
[TBL] [Abstract][Full Text] [Related]
16. Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.
Lavacchi D; Caliman E; Rossi G; Buttitta E; Botteri C; Fancelli S; Pellegrini E; Roviello G; Pillozzi S; Antonuzzo L
Pharmacol Ther; 2022 Sep; 237():108170. PubMed ID: 35296436
[TBL] [Abstract][Full Text] [Related]
17. [Not Available].
Valéry M; Cervantes B; Smolenschi C; Boige V; Ducreux M; Cohen R; Hollebecque A
Bull Cancer; 2022 Nov; 109(11S):11S21-11S27. PubMed ID: 36535759
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of ivosidenib for the treatment of
Tella SH; Mahipal A
Expert Opin Pharmacother; 2022 Dec; 23(17):1879-1885. PubMed ID: 36257911
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
Fan B; Dai D; DiNardo CD; Stein E; de Botton S; Attar EC; Liu H; Liu G; Lemieux I; Agresta SV; Yang H
Cancer Chemother Pharmacol; 2020 May; 85(5):959-968. PubMed ID: 32296873
[TBL] [Abstract][Full Text] [Related]
20. Current and emerging therapies for advanced biliary tract cancers.
Kam AE; Masood A; Shroff RT
Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):956-969. PubMed ID: 34626563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
